Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Accumulated Expenses (2022 - 2026)

Compass Therapeutics' Other Accumulated Expenses history spans 5 years, with the latest figure at $708000.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 158.39% to $708000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $708000.0, a 158.39% increase, with the full-year FY2025 number at $484000.0, down 22.06% from a year prior.
  • Other Accumulated Expenses hit $708000.0 in Q1 2026 for Compass Therapeutics, up from $484000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CMPX hit a ceiling of $708000.0 in Q1 2026 and a floor of $96000.0 in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $320500.0 across 5 years, with a median of $277500.0 in 2024.
  • The widest YoY moves for Other Accumulated Expenses: up 158.75% in 2024, down 57.29% in 2024.
  • Tracing CMPX's Other Accumulated Expenses over 5 years: stood at $96000.0 in 2022, then surged by 150.0% to $240000.0 in 2023, then soared by 158.75% to $621000.0 in 2024, then fell by 22.06% to $484000.0 in 2025, then skyrocketed by 46.28% to $708000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for CMPX at $708000.0 in Q1 2026, $484000.0 in Q4 2025, and $141000.0 in Q3 2025.